K201 (JTV-519) prevents calcium induced diastolic dysfunction in rat hearts

被引：0
|
作者：
Loughrey, Christopher M.
Otani, Naoyuki
Matsuda, Ryuko
Kaneko, Noboru
Smith, Godfrey L.
机构：
[1] Univ Glasgow, Glasgow, Lanark, Scotland
[2] Dokkyo Univ, Sch Med, Tochigi, Japan
来源：
BIOPHYSICAL JOURNAL | 2007年
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：76A / 76A
页数：1
相关论文
共 28 条
  • [1] K201 (JTV-519) improves norepinephrine-induced diastolic dysfunction with preservation of the ejection fraction
    Matsuda, R.
    Otani, N.
    Nakajima, T.
    Abe, S.
    Shinozaki, M.
    Hasumi, H.
    Kikuchi, M.
    Kaneko, N.
    EUROPEAN HEART JOURNAL, 2007, 28 : 145 - 145
  • [2] K201 (JTV-519) alters the spatiotemporal properties of diastolic Ca2+ release and the associated diastolic contraction during β-adrenergic stimulation in rat ventricular cardiomyocytes
    Elliott, E. B.
    Hasumi, H.
    Otani, N.
    Matsuda, T.
    Matsuda, R.
    Kaneko, N.
    Smith, G. L.
    Loughrey, Christopher M.
    BASIC RESEARCH IN CARDIOLOGY, 2011, 106 (06) : 1009 - 1022
  • [3] K201 (JTV-519) alters the spatiotemporal properties of diastolic Ca2+ release and the associated diastolic contraction during β-adrenergic stimulation in rat ventricular cardiomyocytes
    E. B. Elliott
    H. Hasumi
    N. Otani
    T. Matsuda
    R. Matsuda
    N. Kaneko
    G. L. Smith
    Christopher M. Loughrey
    Basic Research in Cardiology, 2011, 106 : 1009 - 1022
  • [4] Effects of K201 (JTV-519) on excitation-contraction coupling and Ca2+ release in rat ventricular cardiomyocytes
    Otani, N.
    Matsuda, R.
    Toyoda, S.
    Matsuda, T.
    Kaneko, N.
    Loughrey, C. M.
    Smith, G. L.
    EUROPEAN HEART JOURNAL, 2007, 28 : 178 - 178
  • [5] K201 (JTV519), a novel cardioprotective agent, prevents torsades de pointes induced by the K+ channel blocker, clofilium
    Matsuda, R.
    Matsuda, T.
    Shinozaki, M.
    Ohtani, N.
    Taguchi, I.
    Kikuchi, M.
    Kaneko, N.
    EUROPEAN HEART JOURNAL, 2006, 27 : 196 - 196
  • [6] Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
    Dincer, U. Deniz
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2012, 5 : 89 - 99
  • [7] JTV-519 (K201) reverses abnormal Ca2+ release and dynamic Ca2+ waves in Purkinje cells from the infarcted canine heart
    Hirose, Masanori
    Stuyvers, Bruno
    Dun, Wen
    Shimokawa, Hiroaki
    ter Keurs, Henk E. D. J.
    Boyden, Penelope
    CIRCULATION, 2007, 116 (16) : 84 - 84
  • [8] K201 improves norepinephrine-induced diastolic dysfunction with preserved ejection fraction
    Kaneko, Noboru
    Matsuda, Ryuko
    Ohtani, Naoyuki
    Nakajima, Takahide
    Arikawa, Takuo
    Suzuki, Hidehiko
    Toyoda, Shigeru
    Kikuchi, Migaku
    Hata, Yoshihito
    Abe, Shichiro
    Taguchi, Isao
    Shimamoto, Ken
    DRUG DEVELOPMENT RESEARCH, 2006, 67 (11) : 852 - 861
  • [9] Protective effect of JTV519 (K201), a new 1,4-benzothiazepine derivative, on prolonged myocardial preservation
    Hachida, M
    Lu, H
    Kaneko, N
    Horikawa, Y
    Ohkado, A
    Gu, H
    Zhang, XL
    Hoshi, H
    Nonoyama, M
    Nakanishi, T
    Koyanagi, H
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 996 - 1000
  • [10] K201 (JTV519) is a Ca2+-Dependent Blocker of SERCA and a Partial Agonist of Ryanodine Receptors in Striated Muscle
    Darcy, Yuanzhao L.
    Diaz-Sylvester, Paula L.
    Copello, Julio A.
    MOLECULAR PHARMACOLOGY, 2016, 90 (02) : 106 - 115
123